Dong Yi, Cao Wenjie, Ren Jinma, Nair Deepak S, Parker Sarah, Jahnel Jan L, Swanson-Devlin Teresa G, Beck Judith M, Mathews Maureen, McNeil Clayton J, Upadhyaya Manas, Gao Yuan, Dong Qiang, Wang David Z
Department of Neurology, Huashan Hospital, State Key of Laboratory of Neurobiology, Fudan University at Shanghai, Shanghai, China; INI Stroke Network, OSF Healthcare System, Department of Neurology, University of Illinois College of Medicine at Peoria, Peoria, IL, United States of America.
Department of Neurology, Huashan Hospital, State Key of Laboratory of Neurobiology, Fudan University at Shanghai, Shanghai, China.
PLoS One. 2015 Aug 6;10(8):e0131487. doi: 10.1371/journal.pone.0131487. eCollection 2015.
Intravenous (i.v.) tissue-type plasminogen activator (tPA) is the only approved noninvasive therapy for acute ischemic stroke (AIS). However, after tPA treatment, the outcome of patients with different subtypes of stroke according to their vascular risk factors remains to be elucidated. We aim to explore the relationship between the outcome and different risk factors in patients with different subtype of acute strokes treated with i.v. tPA. Records of patients in this cohort were reviewed. Data collected and analysed included the demographics, vascular risk factors, baseline National Institutes of Health Stroke Scale (NIHSS) scores, 90-day modified Rankin Scores (mRS), and subtypes of stroke. By using the 90-day mRS, patients were dichotomized into favorable versus unfavorable outcome in each subtype of stroke. We identified the vascular risk factors that are likely associated with the poor outcome in each subtype. Among 570 AIS patients received i.v. tPA, 217 were in the large artery atherosclerosis (LAA) group, 146 in the small vessel occlusion (SVO) group, and 140 in the cardioaortic embolism (CE) group. Lower NIHSS score on admission was related to favorable outcome in patients in all subtypes. Patients with history of dyslipidemia were likely on statin treatment before their admission and hence less likely to have elevated cholesterol level on admission. Therefore, there was a possible paradoxical effect on the outcome in patients with LAA and SVO subtypes of strokes. SVO patients with history of diabetes had higher risk of unfavorable outcome. SVO patients had favorable outcome if their time from onset to treatment was short. In conclusion, the outcome of patients treated with i.v. tPA may be related to different vascular risk factors associated with different subtypes of stroke.
静脉注射组织型纤溶酶原激活剂(tPA)是唯一被批准用于急性缺血性卒中(AIS)的非侵入性治疗方法。然而,tPA治疗后,根据血管危险因素划分的不同亚型卒中患者的预后仍有待阐明。我们旨在探讨接受静脉注射tPA治疗的不同亚型急性卒中患者的预后与不同危险因素之间的关系。对该队列中患者的记录进行了回顾。收集和分析的数据包括人口统计学、血管危险因素、美国国立卫生研究院卒中量表(NIHSS)基线评分、90天改良Rankin量表评分(mRS)以及卒中亚型。通过使用90天mRS,将每种卒中亚型的患者分为预后良好和预后不良两组。我们确定了每种亚型中可能与预后不良相关的血管危险因素。在570例接受静脉注射tPA的AIS患者中,217例属于大动脉粥样硬化(LAA)组,146例属于小血管闭塞(SVO)组,140例属于心源性栓塞(CE)组。入院时较低的NIHSS评分与所有亚型患者的良好预后相关。有血脂异常病史的患者在入院前可能接受了他汀类药物治疗,因此入院时胆固醇水平升高的可能性较小。因此,对于LAA和SVO亚型卒中患者的预后可能存在矛盾效应。有糖尿病病史的SVO患者预后不良的风险较高。如果SVO患者从发病到治疗的时间较短,则预后良好。总之,接受静脉注射tPA治疗的患者的预后可能与不同亚型卒中相关的不同血管危险因素有关。